One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis

Background Studies showed that the endotoxemia-related biomarker, lipopolysaccharide-binding protein (LBP), is associated with obesity and fatty liver. The level of LBP is reduced after surgical weight loss. This study aimed to verify the change of serum LBP levels after one-year medical weight management in subjects with obesity. Methods and findings A total of 62 subjects with obesity, 39 subjects with overweight, and 21 subjects with normal body mass index were enrolled for a one-year weight management program. Basic information, body composition analysis, clinical data, serum LBP level, and abdominal ultrasonography findings were collected. At baseline, the serum LBP levels of the obese and overweight subjects were significantly higher than that of the normal group (30.9±7.4 and 29.6±6.3 versus 23.1±5.6 μg/mL, respectively, p<0.001). Serum LBP in subjects with obesity was significantly reduced to 26.5±7.1 μg/mL (p-value < 0.001) after one year. In the multivariate analyses, LBP was associated with high sensitive C-reactive protein (hs-CRP) and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) before weight management in the obese group. Moreover, the change of LBP in response to weight management was significantly related to the changes of hs-CRP, leukocyte count and NFS by multivariate linear regression analysis also in the obese group. Conclusion The serum level of the endotoxemia-related biomarker, LBP, decreases after one-year weight management in the obese subjects. In addition to serving as a metainflammatroy biomarker like hs-CRP, LBP may also be a potential biomarker as a non-invasive biomarker for the evaluation of liver fibrosis in NAFLD.

[1]  F. Hu,et al.  A Marker of Endotoxemia Is Associated With Obesity and Related Metabolic Disorders in Apparently Healthy Chinese , 2010, Diabetes Care.

[2]  G. Gores,et al.  Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. , 2008, Seminars in liver disease.

[3]  C. Apovian,et al.  Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies , 2015, Obesity.

[4]  F. Celi,et al.  Effects of a 12-Month Moderate Weight Loss Intervention on Insulin Sensitivity and Inflammation Status in Nondiabetic Overweight and Obese Subjects , 2014, Hormone and Metabolic Research.

[5]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[6]  M. Gayda,et al.  Intensive lifestyle intervention improves cardiometabolic and exercise parameters in metabolically healthy obese and metabolically unhealthy obese individuals. , 2014, The Canadian journal of cardiology.

[7]  J. Crespo,et al.  Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis , 2007, Obesity surgery.

[8]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[9]  J. Weiss,et al.  Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. , 2003, Biochemical Society transactions.

[10]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[11]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[12]  Yan Wang,et al.  Correlation of TLR4 and KLF7 in Inflammation Induced by Obesity , 2017, Inflammation.

[13]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[14]  P. Pickhardt,et al.  Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. , 2016, The British journal of radiology.

[15]  R. Schumann.  Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. , 2011, Biochemical Society transactions.

[16]  J. Kao,et al.  High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments , 2017, PloS one.

[17]  F. Gudé,et al.  Determinants of Serum Concentrations of Lipopolysaccharide-Binding Protein (LBP) in the Adult Population: The Role of Obesity , 2013, PloS one.

[18]  Liping Zhao,et al.  A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome , 2013, FEMS microbiology ecology.

[19]  L. Putignani,et al.  Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. , 2010, Endocrine reviews.

[20]  Ming-Tsan Lin,et al.  Bariatric surgery decreased the serum level of an endotoxin-associated marker: lipopolysaccharide-binding protein. , 2014, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[21]  F. Violi,et al.  Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS) , 2012, Internal and Emergency Medicine.

[22]  M. Pedroso,et al.  Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist? , 2017, Archives of endocrinology and metabolism.

[23]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[24]  J. Moreno-Navarrete,et al.  Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance , 2012, International Journal of Obesity.

[25]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[26]  V. Wong,et al.  Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study , 2015, Alimentary pharmacology & therapeutics.

[27]  J. Moreno-Navarrete,et al.  Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. , 2013, Atherosclerosis.

[28]  S. Morini,et al.  Hepatic toll‐like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD , 2015, Liver international : official journal of the International Association for the Study of the Liver.